Since 1999, Mr Bailey has held leadership positions of increasing responsibility at ImClone Systems. Most recently he led ImClone’s worldwide commercial organization, responsible for commercial aspects for the planning and launch of Erbitux across multiple indications.
Mr Bailey earned a BS in psychology and MBA in international marketing by graduating with honors from both St Lawrence University and the University of Notre Dame Graduate School of Business.
Safi Bahcall, president and CEO of Synta, said: “Michael Bailey brings to Synta a terrific combination of knowledge, skills, and experience including first-hand responsibility for a recent blockbuster oncology product launch; the ability to thrive in a fast-paced and growing biotechnology company; and the skills to succeed in a joint development and commercialization alliance.”